Nordson (NDSN) Q4 2025 earnings review
Record Margins Mask Organic Stagnation
Nordson delivered a masterclass in efficiency but struggled to find organic growth in Q4. While Adjusted EPS grew 9% to $3.03 and EBITDA margin hit a record 34%, the top line was flat (+1%). Critically, organic sales fell 1%, dragged down by a sudden reversal in the Advanced Technology Solutions (ATS) segment. The growth baton has passed from Electronics to Medical, with the Medical segment posting its first strong organic growth quarter (+7%) of the year. Management's FY26 guidance suggests confidence in a broader cyclical recovery, forecasting sales of $2.83-2.95B.
🐂 Bull Case
Medical and Fluid Solutions (MFS) has decisively turned the corner. After three quarters of organic contraction (including double-digit declines in H1), MFS posted +7% organic growth in Q4. EBITDA margin in this segment surged to 40%, up 380bps YoY.
Nordson is squeezing maximum value from every dollar of sales. EBITDA margin expanded to a record 34% (up from 32%), and Free Cash Flow conversion hit a staggering 128% of Net Income. The NBS Next framework is delivering tangible bottom-line results despite sluggish volume.
🐻 Bear Case
The Advanced Technology Solutions (ATS) segment—the star performer in Q2 and Q3—reversed sharply. After growing ~15-18% organically in mid-year, it shrank 5% organically in Q4 due to weaker test/inspection system deliveries. This unpredictability ('lumpiness') remains a risk.
Industrial Precision Solutions (IPS), the largest segment, remains a drag. Sales fell 2% (-4% organic) as polymer processing weakness continues to offset gains elsewhere. This segment has failed to grow organically for the entire fiscal year.
⚖️ Verdict: ⚪
Neutral. The operational discipline is superb, earning the premium valuation. However, the sudden drop in Electronics (ATS) demand raises questions about the durability of the 'AI-driven' growth narrative. The investment thesis now relies on the FY26 guidance for a synchronized recovery across end markets.
Key Themes
Medical Segment (MFS) Recovery Confirmed
Reversing. The Medical segment has officially exited its destocking phase. After struggling with negative organic growth throughout FY25, Q4 delivered a strong +7% organic gain. Coupled with the integration of the Atrion acquisition, MFS revenue grew 10% YoY. More importantly, profitability soared, with EBITDA margins hitting 40%.
Advanced Technology (ATS) Hits an Air Pocket
Reversing. The narrative that ATS is a steady secular grower driven by AI/Chips took a hit. After posting organic growth of +18.1% in Q2 and +14.6% in Q3, the segment contracted 5% organically in Q4. Management cited fewer deliveries of x-ray inspection systems. While EBITDA margin is healthy (25%), the volatility makes this segment difficult to model.
Record Profitability in a Flat Macro
Stable/Accelerating. Nordson's ability to protect and expand margins is the highlight of the report. Despite organic sales falling 1%, Adjusted Net Income rose 7%. The company achieved a record full-year EBITDA of $900M. The 128% Free Cash Flow conversion indicates high earnings quality and efficient working capital management.
Industrial Precision (IPS) Still Searching for a Bottom
Stable (Weak). The largest segment (IPS) continues to bleed slowly, down 2% YoY and 4% organically. Double-digit weakness in polymer processing systems remains the primary culprit. This cyclical headwind has persisted for four quarters, dampening the overall company recovery.
Backlog Building
Accelerating. The company enters FY26 with $600M in backlog, up 5% year-over-year (excluding divested businesses). This supports the FY26 guidance for growth and suggests book-to-bill ratios are improving, specifically in areas outside of the currently weak polymer processing.
Other KPIs
Stable. +1% YoY. Organic sales declined 1%, offset by FX (+2%) and M&A (+1%). This beat the slight pessimist view but missed the growth trajectory set in Q3.
Accelerating. +9% YoY. Operational efficiency drove EPS growth significantly higher than revenue growth (1%).
Accelerating. Record cash flow, up 34% YoY ($492M in FY24). Conversion rate of 136% of Net Income is exceptional.
Guidance
Accelerating. The midpoint ($2.89B) implies ~3.5% growth over FY25's $2.79B. This suggests management sees a return to organic growth across the portfolio.
Accelerating. The midpoint ($11.15) implies ~9% growth YoY. Management continues to leverage flat-to-low sales growth into high-single-digit earnings growth.
Accelerating. Midpoint ($650M) implies +5.7% YoY growth vs 25Q1 ($615M). This confirms the backlog strength is translating to immediate sales.
Accelerating. Midpoint ($2.35) implies +14% YoY growth vs 25Q1 ($2.06). Strong margin performance is expected to continue.
Key Questions
ATS Volatility
Electronics/ATS swung from +15% organic growth in Q3 to -5% in Q4. Is this purely timing of X-ray system deliveries, or has the underlying demand signal for semiconductor packaging weakened?
IPS Polymer Weakness
Polymer processing has been a drag on IPS for a full year. Do you see a bottom in 1H FY26, or should we model this segment as a headwind for the full fiscal year?
Capital Allocation
With record free cash flow ($661M) and leverage well under control, why only $300M in share repurchases YTD? Should we expect accelerated buybacks in FY26 given the strong cash conversion?